Management strategies for hepatitis B-infected patients undergoing immunomodulatory therapy: Is lamivudine enough?
作者信息
Terrault Norah
机构信息
Department of Medicine University of California San Francisco San Francisco CA.
出版信息
Clin Liver Dis (Hoboken). 2015 Mar 27;5(2):43-46. doi: 10.1002/cld.447. eCollection 2015 Feb.
Abstract
摘要
相似文献
1
Management strategies for hepatitis B-infected patients undergoing immunomodulatory therapy: Is lamivudine enough?接受免疫调节治疗的乙型肝炎感染患者的管理策略：拉米夫定是否足够？
Clin Liver Dis (Hoboken). 2015 Mar 27;5(2):43-46. doi: 10.1002/cld.447. eCollection 2015 Feb.
2
Management of viral hepatitis B.乙型病毒性肝炎的管理
J Gastroenterol Hepatol. 2002 Feb;17 Suppl:S125-45. doi: 10.1046/j.1440-1746.17.s1.3.x.
3
Short-term lamivudine for the treatment of chronic hepatitis B.短期使用拉米夫定治疗慢性乙型肝炎。
Intervirology. 2003;46(6):367-72. doi: 10.1159/000074994.
4
Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management.接受化疗的乳腺癌患者中的乙型肝炎病毒再激活：预防管理的综述与荟萃分析
J Viral Hepat. 2017 Jul;24(7):561-572. doi: 10.1111/jvh.12672. Epub 2017 Feb 5.
5
Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients.粒细胞巨噬细胞集落刺激因子或拉米夫定联合重组干扰素对乙型肝炎病毒相关慢性肝病患者中干扰素无应答者的疗效。
J Gastroenterol Hepatol. 2002 Jul;17(7):765-71. doi: 10.1046/j.1440-1746.2002.02794.x.
6
Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model.淋巴瘤化疗患者的乙肝预防：一种决策分析模型
Hepatology. 2007 Oct;46(4):1049-56. doi: 10.1002/hep.21783.
7
Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy.一名接受细胞毒性化疗的HIV感染患者中拉米夫定耐药隐匿性乙型肝炎的再激活。
J Clin Virol. 2007 May;39(1):48-50. doi: 10.1016/j.jcv.2007.01.011. Epub 2007 Mar 21.
8
Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.在未接受过治疗的乙型肝炎病毒（HBV）感染患者中，无论是否合并感染HIV，与拉米夫定耐药相关的突变：对南非HBV和HIV合并感染患者抗逆转录病毒治疗的影响
J Med Virol. 2007 Nov;79(11):1650-4. doi: 10.1002/jmv.20974.
9
Lamivudine facilitates optimal chemotherapy in hepatitis B virus-infected children with hematological malignancies: a preliminary report.拉米夫定有助于乙型肝炎病毒感染的血液系统恶性肿瘤患儿进行最佳化疗：初步报告。
Pediatr Hematol Oncol. 2004 Mar;21(2):145-56. doi: 10.1080/08880010490273019.
10
Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin.拉米夫定治疗乙型肝炎病毒前核心突变相关感染的肝移植患者：治疗复发时耐药率高，但与极低剂量乙型肝炎免疫球蛋白联合用作预防时可普遍预防复发。
Liver Transpl Surg. 1999 Nov;5(6):512-9. doi: 10.1002/lt.500050601.
引用本文的文献
1
Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations.免疫抑制患者中乙肝再激活的管理：当前推荐的最新进展。
World J Hepatol. 2016 Mar 18;8(8):385-94. doi: 10.4254/wjh.v8.i8.385.
本文引用的文献
1
American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.美国胃肠病学会关于免疫抑制药物治疗期间预防和治疗乙型肝炎病毒再激活的技术审查
Gastroenterology. 2015 Jan;148(1):221-244.e3. doi: 10.1053/j.gastro.2014.10.038. Epub 2014 Oct 31.
2
Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: a systematic review and meta-analysis.预防性使用拉米夫定改善化疗期间HBsAg阳性淋巴瘤患者的预后：一项系统评价和荟萃分析。
Clin Res Hepatol Gastroenterol. 2015 Feb;39(1):80-92. doi: 10.1016/j.clinre.2014.07.010. Epub 2014 Sep 4.
3
Lamivudine compared with newer antivirals for prophylaxis of hepatitis B core antibody positive livers: a cost-effectiveness analysis.
Am J Transplant. 2014 Mar;14(3):629-34. doi: 10.1111/ajt.12598. Epub 2014 Jan 24.
4
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study.化疗引起的已治愈乙型肝炎病毒感染淋巴瘤患者的肝炎再激活：一项前瞻性研究。
Hepatology. 2014 Jun;59(6):2092-100. doi: 10.1002/hep.26718. Epub 2014 Apr 14.
5
Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.利妥昔单抗治疗的 B 细胞淋巴瘤患者乙型肝炎病毒再激活：亚洲淋巴瘤研究组的分析。
Eur J Cancer. 2013 Nov;49(16):3486-96. doi: 10.1016/j.ejca.2013.07.006. Epub 2013 Aug 1.
6
7
Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.恩替卡韦与拉米夫定用于血液病患者乙型肝炎的预防。
Liver Int. 2013 Sep;33(8):1203-10. doi: 10.1111/liv.12154. Epub 2013 Mar 24.
8
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.欧洲肝脏研究学会临床实践指南：慢性乙型肝炎病毒感染的管理
J Hepatol. 2012 Jul;57(1):167-85. doi: 10.1016/j.jhep.2012.02.010. Epub 2012 Mar 20.
9
Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy.恩替卡韦和拉米夫定在预防淋巴瘤患者化疗期间乙型肝炎病毒再激活中的比较。
J Viral Hepat. 2011 Dec;18(12):877-83. doi: 10.1111/j.1365-2893.2010.01386.x. Epub 2010 Nov 5.
10
Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis.肝移植后供体和受体来源隐匿性乙型肝炎病毒感染，尽管有核苷类似物预防。
Liver Transpl. 2010 Nov;16(11):1314-23. doi: 10.1002/lt.22169.
Zotero 插件